Postpartum Depression Treatment Market

Postpartum Depression Treatment Market Size

The global postpartum depression treatment market size was valued at USD 1 billion in 2024 and is estimated to grow at a CAGR of 9.2% from 2025 to 2034. The demand is largely attributed to the growing global focus on mental well-being among women during childcare.

There is also an increasing burden of PPD, especially among mothers, which has increased the need for better postpartum depression treatment. The introduction of brexanolone (Zulresso) has, in many ways, increased the options available, which also lets clinicians address the more complicated sides of the disorder. Global improvements in healthcare and the aforementioned factors are anticipated to accelerate the growth rate of the industry in the future.

The growing knowledge and awareness of maternal mental health is another core driver. Improved conversations on the postpartum stage are a result of public health approaches and the engagement and screening of the condition in postnatal care practices, which encourages women to show up for care. All these factors placed together present this kind of market with possibilities of growing robustly.

Mood disorder is what postpartum depression falls under, as it is a type of stress affecting women immediately after giving birth. Accountability, bonding with the baby, a feeling of dread and fatigue, anxiety, and irritability are all symptoms associated with postpartum depression. It may affect mother-infant attachment and day-to-day activity, and in extreme circumstances, it may endanger both mother and baby. In many ways, postpartum depression can be treated. It’s aimed at meeting emotional, hormonal, and physical needs so as to facilitate the recovery of mothers. This treatment includes the use of antidepressants and hormones.

Postpartum Depression Treatment Market Trends

One reason that is likely to contribute to the advancement of the industry dealing with the treatment of postpartum depression is the growing prevalence of the disease.

• As observed in a survey done by Postpartum Depression Organization, it has been estimated that 1 out of 10 women experience depression following the birth of a child, however, other research suggests the ratio to be approximately 1:7. Enhancing global lifestyle, increasing stress, and hormonal imbalance are attributed as the primary reasons for the growing numbers of PPD cases.
  
• This increasing prevalence also emphasizes the need for treatment options for postpartum depression that are effective enough, resulting in an amalgamation of awareness, innovation, and funding in the PPD treatment market for the welfare of mothers and their families to address the raised concern.
  
• The treatment-seeking behavior is also driven by the diagnosis and treatment of the condition due to its increased awareness by women, thus further developing the existing demand of the market.
  
• On the extreme end of treatment options, brexanolone is helping to treat mothers suffering from severe PPD, while traditional antidepressants can take longer to relieve the symptoms. This is due to brexanolone being a relatively new therapy.
  

Postpartum Depression Treatment Market Analysis

Learn more about the key segments shaping this market

Download Free PDF

Based on the type, the market is segmented into postpartum anxiety, postpartum blues, postpartum post-traumatic stress disorder (PTSD), postpartum obsessive-compulsive disorder (OCD), postpartum panic disorder, and postpartum psychosis. The postpartum anxiety segment dominated the market with a 23.5% share in 2024.

• A core concern of postpartum depression is postpartum anxiety, which is an issue affecting a significant proportion of women who have recently given birth. For example, the National Institutes of Health explains that although the average levels of anxiety may reduce after the baby is born, still 1 in 5 women are found to be quite anxious in the postpartum period, which demands management of the condition.
  
• Moreover, a growing emphasis on maternal mental health, especially in cultures where seeking help remains a taboo, has significantly enhanced both diagnostic quality and treatment uptake.
  
• In addition, the emergence of telemedicine and digital solutions has greatly improved the availability and accessibility of easily attainable care in underdeveloped regions.
  
• The factors mentioned above work together to bolster the growth of the postpartum anxiety segment in the market.
  

Based on the treatment, the postpartum depression treatment market is categorized into pharmacotherapy, hormone therapy, and other treatments. The pharmacotherapy segment is further sub-categorized into selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCA), and other pharmacotherapies. The pharmacotherapy segment was valued at USD 549.8 million in 2024 and is poised to grow at 9.1% CAGR.

• The expansion of this area has been enabled by an increase in the need for treatment, new forms of therapy, and improved availability of treatment.
  
• One of the primary drivers of this segment is the proven efficacy of pharmacotherapy in treating PPD symptoms. Selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors (both types of antidepressants) are frequently prescribed because they are safe and effective for the management of anxiety and depression when they occur together.
  
• In addition, the high prevalence of anxiety with postpartum depression has fueled the need for medications which treat both conditions like SSRIs and SNRIs.

Learn more about the key segments shaping this market

Download Free PDF

Based on the route of administration, the postpartum depression treatment market is divided into oral, parenteral, and other routes of administration. The oral segment accounted for the highest market share and is expected to reach USD 1.5 billion by the end of the analysis period.

• This dominance is mostly stimulated by convenience of use associated with oral medication. In particular, for new mothers who have to take care of a baby, oral medications are easy to self-administer without the need for supervision or procedures.
  
• Widespread availability of oral antidepressants is also a factor that is going to boost this segment.
  
• In addition, oral medications' ability to be used for a long time fits perfectly with PPD, which most of the time needs long-term treatment.
  
• With these benefits, the prophecy is that the segment covering oral medication will grow significantly during the specified period.
  

Based on the distribution channel, the postpartum depression treatment market is classified into hospital pharmacies, retail pharmacies, and online pharmacies. In 2024, the hospital pharmacies segment held 47.2% of market share.

• Hospital pharmacies are at the forefront of the distribution of complex therapies and medications like brexanolone (Zulresso) which is the first drug approved by FDA for treatment of postpartum depression. It is is exclusively administered in hospitals, as it is needed to be given intravenously with medical supervision. Hence, hospitals’ pharmacies are very important for these therapies.
  
• Their superiority is also reinforced by the fact that pharmacies in hospitals are intergrated with the inpatient and outpatient care systems.
  
• Also, the presence of professionals enhances the safety and efficacy of medication use, which in turn increases the business of hospital pharmacies. 

Looking for region specific data?

Download Free PDF

In 2024, the U.S. postpartum depression therapeutic market was valued at USD 370.7 million and for the forthcoming years it is expected to grow at 8.9% CAGR.

• The factors such as increasing rates of postpartum depression in women, rising maternal mental health awareness, and advanced treatment options coming into the market are propelling the growth of this country.
  
• Furthermore, the strong infrastructure of the U.S. healthcare system, as well as PPD treatment policies and insurance coverage for mental health conditions have all enabled and facilitated the use and implementation of PPD treatments.
  

Germany postpartum depression treatment market is expected to experience significant growth.

• The development of telemedicine platforms in Germany is aiding in widening the scope of mental health services, especially for women who reside in rural or neglected regions which increases treatment uptake.
  
• In addition, the country's robust pharmaceutical and biotechnology sectors are concentrating on the development of novel PPD therapies. Such focus on innovation will provide more treatment alternatives in the near future.
  

India postpartum depression treatment market is anticipated to witness high growth during the forecast period.

• As per information from National Institutes of Health, an estimated 22% new mothers in India suffer from PPD which substantiates an emerging need for effective treatments.
  
• Diverse factors such as social and cultural pressures, lack of support structures, and hormonal changes after childbirth lead to such high numbers. More people are understanding and being aware of this issue which is boosting the need for focused treatments to manage and treat PPD strategically.
  
• Also, with the emergence of nuclear families, and parents working, the new mother in India does not have any support systems, and this is contributing to the important recognition of postpartum mental healthcare challenges. This shift in society is increasing the need for officially defined PPD treatments.
  

Brazil postpartum depression treatment market is predicted to sharpen during the analysis phase.

• As far as the market is concerned this expectation is based on and stems from increased understanding of women’s mental wellbeing, better healthcare facilities, and higher rates of PPD.
  
• Further, the development in the region's health sector, especially after the introduction of cheap antidepressant medications by domestic manufacturers, is also making seeking treatment easier.
  
• Additionally, collaboration between the healthcare industry and non-profit organizations is improving marketing outreach and therefore fueling market expansion.
  

The market of postpartum depression treatment in Saudi Arabia is very likely to be on the rise in the upcoming years.

• The altered population is projected to grow fiercely with increased awareness of mental wellbeing, shifting attitudes of cultures, and improved access to health services.
  
• The shift in cultures is diminishing stigma associated with seeking aide for one’s mental state which in turn supplies women with the approach to seeking treatment.
  
• Moreover, integrating enhanced therapies along with government initiatives supporting maternal and child wellbeing will significantly accelerate the early identification and treatment of PPD all over the country.
  

Postpartum Depression Treatment Market Share

The postpartum depression treatment space has a number of players competing for market share by offering new therapies and forming partnerships. Sage Therapeutics, Biogen, Pfizer, and GSK are already capturing a portion of this market due to their strong research and development focus and the development of new pharmacological therapies. The formation of strategic partnerships, mergers, and acquisitions are normal as companies look to grow their geographic presence and improve their product base.

Postpartum Depression Treatment Market Companies

Few of the prominent players operating in the postpartum depression treatment industry include:

• Bausch Health Companies
• Biogen 
• Cipla
• Eli Lilly and Company
• GSK
• Merck
• Novartis
• Pfizer
• Sage Therapeutics
• Teva Pharmaceutical Industries
  

USPs for top players:

• Greater emphasis on patient-friendly solutions providing accessible, affordable treatments and minimal side effects.
  
• Investment in research and development of novel therapeutic compounds targeting postpartum depression.
  
• Strategic collaborations for the development of innovative drug delivery systems to improve patient compliance and treatment outcomes.
  

Postpartum Depression Treatment Industry News

• In August 2023, Sage Therapeutics, Inc. and Biogen Inc. announced that the U.S. Food and Drug Administration has approved ZURZUVAETM (zuranolone) 50 mg for the treatment of adults with postpartum depression (PPD). This helped the companies to strengthen their product portfolio and generate revenue.
  

The postpartum depression treatment market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Type

• Postpartum anxiety
• Postpartum blues
• Postpartum post-traumatic stress disorder (PTSD)
• Postpartum obsessive-compulsive disorder (OCD)
• Postpartum panic disorder
• Postpartum psychosis

Market, By Treatment

• Pharmacotherapy
  • Selective serotonin reuptake inhibitors (SSRIs)
  • Serotonin norepinephrine reuptake inhibitors (SNRIs)
  • Tricyclic antidepressants (TCA)
  • Other pharmacotherapies 
• Hormone therapy
• Other treatments

Market, By Route of Administration

• Oral
• Parenteral
• Other routes of administration

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina 
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE